Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Clinical trial NCT01915602 · COMPLETED

Trial details

NCT number: NCT01915602
Sponsor: Bayer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Hepatocellular

Start date: 2013-09-27
Primary completion: 2015-07-29
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.